Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Net Margin (2016 - 2025)

Historic Net Margin for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to 101.57%.

  • Ligand Pharmaceuticals' Net Margin changed N/A to 101.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.34%, marking a year-over-year change of. This contributed to the annual value of 2.41% for FY2024, which is 11400.0% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Net Margin stood at 101.57% for Q3 2025.
  • Ligand Pharmaceuticals' 5-year Net Margin high stood at 101.57% for Q3 2025, and its period low was 93.64% during Q1 2025.
  • Its 5-year average for Net Margin is 11.21%, with a median of 7.25% in 2021.
  • Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Net Margin showed a top increase of 627700bps in 2021 and a maximum decrease of -605700bps in 2021.
  • Ligand Pharmaceuticals' Net Margin (Quarter) stood at 3.94% in 2021, then crashed by -49bps to 5.86% in 2022, then skyrocketed by 35bps to 3.79% in 2023, then plummeted by -1818bps to 72.62% in 2024, then skyrocketed by 240bps to 101.57% in 2025.
  • Its Net Margin stands at 101.57% for Q3 2025, versus 10.18% for Q2 2025 and 93.64% for Q1 2025.